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Abstract 
Striatal abnormalities play a crucial role in the pathophysiology of schizophrenia. Growing 
evidence suggests an association between aberrant striatal activity during reward anticipation and 
symptom dimensions in schizophrenia. However, it is not clear whether this holds across the 
psychosis continuum. The aim of the present study was to investigate alterations of ventral 
striatal activation during reward anticipation and its relationship to symptom expression in 
persons with schizotypal personality traits and first-episode psychosis. 26 individuals with high 
schizotypal personality traits, 26 patients with non-affective first-episode psychosis (including 13 
with brief psychotic disorder and 13 with first-episode schizophrenia) and 25 healthy controls 
underwent event-related functional magnetic resonance imaging while performing a variant of the 
monetary incentive delay task. Ventral striatal was positively correlated with total symptom 
severity, in particular the level of positive symptoms. This association was observed across the 
psychosis continuum and within each subgroup. Patients with first-episode schizophrenia showed 
the strongest elevation of striatal activation during reward anticipation, although symptom levels 
did not differ between groups in the psychosis continuum. While our results provide evidence 
that variance in striatal activation is mainly explained by dimensional symptom expression, 
patients with schizophrenia show an additional dysregulation of striatal activation. Trans-
diagnostic approaches are promising in order to disentangle dimensional and categorical neural 
mechanisms in the psychosis continuum. 
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Introduction 
Neuroimaging studies have provided increasing evidence for striatal abnormalities as a core 
deficit in the pathophysiology of schizophrenia.1–6 In this context, functional magnetic resonance 
imaging (fMRI) research has suggested that the blood-oxygen-level dependent (BOLD) signal 
during reward anticipation could serve as a marker to investigate striatal dysfunctions in 
patients.7–9  
 
While a picture of striatal dysfunction and its association with symptoms begins to emerge for 
patients with chronic schizophrenia, it is not clear whether this extends across a continuum of 
psychosis (figure 1A). In a psychosis continuum concept, schizotypy and early psychosis can be 
described as at-risk stages for the development of chronic schizophrenia, the extreme end of the 
continuum.10–12 Furthermore, psychotic-like symptoms and schizotypal traits in healthy 
individuals contribute to social disabilities even on a subclinical level.12–14 However, 
neuroimaging studies investigating striatal activation during reward anticipation across a broad 
spectrum of psychosis remain sparse and inconclusive. Compared to healthy controls, differences 
in ventral striatal activity were observed in studies in patients with first-episode schizophrenia 
and first-degree relatives of patients with schizophrenia.15–18 Other studies including patients with 
broadly defined first-episode psychosis (not restricted to schizophrenia and schizophreniform 
disorder) or individuals at-risk for psychosis did not report any group differences, but focused 
more on the relationship with symptom expression.19–23 This work supports the idea that on a 
group level reduced activation of the striatum may be more strongly related to schizophrenia or 
chronic forms of psychosis than to psychotic disorders in general. Importantly, these divergent 
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findings highlight the importance of using dimensional approaches to investigate the neural basis 
of psychosis rather than restricting research to group differences. 
 
In this context, one important line of research aims to elucidate how striatal dysfunction 
contributes to symptom dimensions in psychosis (figure 1B).9 Again, the most consistent 
evidence comes from studies in schizophrenia reporting an association between negative 
symptoms and blunted striatal activity during reward anticipation mainly in chronic medicated 
patients.24–27 In addition, this association has also been observed in first-degree relatives of 
patients with schizophrenia.18 Concerning positive symptoms, the literature strongly suggests an 
association with diminished striatal activity to relevant stimuli in unmedicated first episode 
psychosis patients and individuals at ultra high risk, which is consistent with the aberrant salience 
model of psychosis.15,21 However, on a meta-analytic level including studies with unmedicated 
and medicated patients the association of neural alterations during reward processing and positive 
symptoms is less clearly delineated.24 Furthermore, the association between striatal dysfunction 
and depressive symptoms is well described within depressive disorders28,29 but data are limited 
for schizophrenia.30,31 Most research did not take into account the neural basis of symptom 
dimensions on a psychosis continuum with broadly defined first-episode psychosis patients or 
individuals with schizotypal personality traits. Only recently, researchers have begun to shed 
light on this important question, but data are still very limited.22,32–34 Importantly, with respect to 
individuals with schizotypal traits no study has ever investigated reward anticipation to identify 
neural correlates of symptom expression.  
 
Therefore, the aim of the present study was threefold: 1) to investigate striatal activation during 
reward anticipation in individuals with schizotypal personality traits and a broad spectrum of 
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patients with first-episode psychosis including patients with schizophrenia and patients with brief 
psychotic disorder, 2) to investigate neural correlates of negative and positive symptoms across 
the psychosis continuum, 3) to identify categorical group differences between the three subgroups 
in the psychosis continuum. Based on previous studies discussed above19,21,23,25,35 we expected 
symptom expression but not group membership to be associated with aberrant ventral striatal 
activity during reward anticipation.  
Methods 
Participants 
Initially, 27 patients with first episode non-affective psychosis (FEP), 27 healthy individuals with 
high schizotypal personality traits (SPT) and 26 healthy control participants (HC) were included. 
Three participants (1 FEP, 1 SPT, 1 HC) were excluded because of head movement during fMRI 
scanning.  
 
Individuals with FEP were recruited during their first psychiatric admission in outpatient (n=6) 
and inpatient (n=20) units of the Psychiatric Hospital of the University of Zurich. All FEP 
patients received a stable dose of atypical antipsychotics. Inclusion criterion was a clinical 
diagnosis of brief psychotic disorder, schizophreniform disorder or schizophrenia confirmed in a 
structured Mini-International Neuropsychiatric Interview for DSM-IV (M.I.N.I).36 We excluded 
participants with any other current DSM-IV axis I disorder (in particular current substance use 
disorder and substance-induced psychotic disorder), lorazepam more than 1mg/d, florid psychotic 
symptoms, i.e. any positive subscale item score five or higher as measured with the Positive and 
Negative Syndrome Scale (PANSS)37, or extrapyramidal side effects.38 Regarding inclusion 
criteria, it has to be noted that patients took part in a larger study protocol and therefore patients 
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with higher psychotic symptom levels had to be excluded to ensure adequate task performance. 
Comorbid lifetime diagnoses of individuals with FEP are provided in the supplement (table S1). 
 
Individuals with schizotypal traits were recruited using an online form of the Schizotypal 
Personality Questionnaire (SPQ).39 956 participants completed the questionnaire (mean score 
16.66 (SD 11.34). Individuals with the highest SPQ total scores (upper 10% of the SPQ total 
score) were invited to participate in the study. Exclusion criteria were any current or past Axis I 
disorder confirmed with the M.I.N.I36 as well as use of psychopharmacological drugs. For further 
details on SPT participants and inclusion criteria of healthy controls see supplementary methods. 
The local ethics committee of the Canton Zurich approved the study, and all participants gave 
written informed consent.  
 
Psychopathological Assessment 
All FEP patients and SPT individuals underwent a detailed psychopathological assessment. 
Severity of positive and negative symptoms was assessed with the PANSS. In order to assess 
psychosis dimensions, we used a five-factor model of the PANSS in our subsequent analysis.40 
To thoroughly assess negative symptoms with regard to the two symptom dimensions of apathy 
(deficits in motivation and pleasure) and diminished expression (blunted affect, alogia), we 
applied the previously used German version of the Brief Negative Symptom Scale (BNSS).25,41–43 
Additionally, we used the Calgary Depression Scale for Schizophrenia (CDSS)44 to identify 
depressive symptoms. For details on clinical and neuropsychological assessment see 
supplementary methods. 
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fMRI Task 
We used a variant of the Monetary Incentive Delay Task (MID) with stimuli based on the Cued-
Reinforcement-Reaction-Time Task (figure 2).25,45,46 In contrast to the original MID Task, we 
employed a task design, in which reward was directly determined by the behavior (response time) 
of participants (supplementary figure S1). This adaptation allowed us to investigate the 
motivational properties of reward anticipation in the presence of action-outcome contingencies. 
Before starting the experiment, we informed all participants that they would receive the 
accumulated amount of money they won during the two experimental sessions. The maximum 
amount of money to be won was 50 Swiss Franc (1 CHF = 1.08 US$). We calculated the amount 
of money to be won for each trial on the basis of the response times of the previous 15 individual 
trials (supplementary figure S1). This approach was used in order to account for individual 
differences in response time and thus ensure constant and similarly high rewards in all groups. 
Excluding two training sessions, the experiment contained two runs with 36 trials of about 10s 
each. The inter-trial interval was jittered from 1s to 9s with a mean of 3.5s. In total, one run lasted 
about 6min.  
 
Behavioral Data Analysis 
We performed a two-way repeated measures analysis of variance (ANOVA) to investigate 
response time, the main behavioral outcome measure in the present study. Group was defined as 
between-subject factor and the different reward conditions (neutral, low, high) as within-subject 
factor. We further calculated reward-related speeding, by subtracting the response time during the 
neutral condition (CHF 0) from the response time during the high reward condition (CHF 2.0), 
which was then divided by the mean of these two conditions.  
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Image Acquisition and Analyses 
For acquisition parameters and image preprocessing see supplementary methods. On the first 
level this event-related design was analyzed with a general linear model (GLM) approach. Three 
separate regressors were modeled for the anticipation phases: anticipation of no reward (CHF 0), 
anticipation of low reward (CHF 0 - 0.40) and anticipation of high reward (CHF 0 - 2.0). For the 
outcome phases we included one regressor for each condition (three basic regressors) and two 
parametrically modulated regressors corresponding to the obtained reward amount, one for the 
low and one for the high reward condition. Additionally, target presentation (one regressor) and 
error trials (three regressors) were modelled as regressors of no interest. In total, the first level 
model included twelve regressors. We used the canonical hemodynamic response function for 
convolving all explanatory variables. To analyze reward anticipation we calculated the reward 
anticipation contrast high reward anticipation (CHF 2.0) versus no reward anticipation (CHF 0). 
At the second level of analysis, we included the resulting individual contrast images of all 
participants in a random-effects model. We assessed within-group activation using one sample t-
tests and between-group activation using two sample t-tests. Our main focus was a region of 
interest analysis of reward anticipation in the ventral striatum (VS).  
Region of Interest Analysis 
In line with our a priori hypothesis, we defined the VS as region of interest (ROI). Coordinates 
for the VS were derived from a meta-analysis of Knutson and colleagues (left: x=-12, y=10, z=-2; 
right: x=10, y=8, z=0, both 9mm spheres including 389 voxels)47, which has been used in 
previous studies in patients with bipolar disorder and schizophrenia.25,48 The mean contrast signal 
for the contrast anticipation of high reward versus no reward was extracted and averaged across 
all voxels in the VS ROI using the REX toolbox (http://web.mit.edu/swg/software.htm).  
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Statistical Analysis 
To identify group differences we performed one-way ANCOVAs with VS activation estimate as 
dependent variable and age and cognition as covariates. 
We tested our main hypothesis by calculating Spearman correlation (rs) at the psychopathological 
and neural level dimensionally across SPT participants and FEP patients. Concerning 
psychopathology, we investigated associations between the symptom dimensions of negative 
symptoms (BNSS apathy factor and BNSS diminished expression factor), positive symptoms 
(PANSS positive factor) and depressive symptoms (CDS total score). At the neural level we 
investigated the association of symptom dimensions with the mean contrast signal in the VS. 
Partial correlations were calculated to identify potential confounding variables. To account for 
the use of two separate VS ROIs (right and left VS), Bonferroni correction for multiple 
comparisons was applied for the main analyses.  
Results 
Demographic and Clinical Data 
Demographic and clinical data area summarized in table 1. 
 
Behavioral Data: Reward Decreases Response Time Across Groups 
Response times showed a significant main effect of reward (F(2, 132)=104.29, p<.001), but no 
significant effect of group (F(2, 74)=1.22, p=.30) or group x reward interaction (F(2, 132)=.97, 
p=.42). Bonferroni post-hoc pairwise comparison of response times revealed significant 
differences between all reward conditions (all ps<.001). These results indicate intact reward-
related speeding in all groups. Accordingly, we did not observe any significant group differences 
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in reward-related speeding (F(2, 74)=.818, p=.44), error rates (χ2(2)=2.34, p=.32), and total gain 
(F(2, 74)=1.65, p=.20).  
 
Psychopathological Data – Group Comparisons 
We found that apathy (U=208.5, p=.02) was significantly higher and global functioning 
(U=199.5, p=.02) significantly lower in the FEP than in the SPT group (table 1). In all other 
psychopathological measures we did not observe any significant group differences between FEP 
and SPT participants (table 1). 
 
Psychopathological Data – Apathy is Associated With Positive Symptoms and Depression 
Across FEP and SPT participants, we found a significant association of apathy with positive 
symptoms (rs=.31, p=.02) and depressive symptoms (rs=.44, p=.001). This symptom overlap 
suggests that apathy may have been secondary due to positive and depressive symptoms. In 
contrast, diminished expression was not correlated with positive symptoms (rs=-.22, p=.12) or 
depressive symptoms (rs=.07, p=.63). Furthermore, there was no significant correlation between 
antipsychotic medication and negative symptoms in FEP patients (table S3). 
  
fMRI Data: VS Activation During Reward Anticipation in All Groups 
A voxel-wise whole-brain analysis of the reward anticipation contrast (high reward anticipation 
vs. no reward anticipation) revealed strong task-related activation in reward coding regions 
including the ventral striatum (supplementary table S2).  
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To address aim 1 of the study (relation of group membership to VS activity) we compared mean 
contrast signal from our a priori defined VS ROI between groups (figure 3A and 3B). We did not 
observe any group differences between HC, FEP patients and SPT participants in the left VS 
(F(2, 74)=.28, p=.75) and right VS (F(2, 74)=.07, p=.93) (figure 3C). Importantly, results did not 
change when controlling for age and cognition as potential confounding variables. Thus, the VS 
showed increased activity related to reward anticipation irrespective of group membership. 
 
fMRI Data: Group Differences of VS Activation During Reward Anticipation within the 
Psychosis Continuum 
In a second group analysis we compared right VS activation during reward anticipation within 
the psychosis spectrum. To investigate potential different underlying neural mechanisms we 
defined three separate subgroups: individuals with high schizotypal personality traits (SPT), 
patients with brief psychotic disorders (FEP-BPD) and patients with first episode schizophrenia 
(FEP-SZ). We observed significant group differences in the right VS during reward anticipation 
(F(2, 46)=4.23, p=.02, adjusted p=.04). Post-hoc tests revealed increased VS activity in FEP-SZ 
compared to FEP-BPD (p=.04, adjusted p=.08) and SPT (p=.008, adjusted p=.016). A post-hoc 
analysis including the high-reward and no-reward conditions separately suggested that these 
effects were mainly driven by relatively stronger activity during anticipation of high reward 
(supplementary figure S3). In contrast, there were no significant differences between FEP-BPD 
and SPT (p=.40). In the left VS no significant group differences were observed (F(2, 46)=2.07, 
p=.14). In sum, these findings provide evidence that right VS activity during reward anticipation 
differs between FEP-SZ and other subgroups within the psychosis continuum. 
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Association of VS Activity With Apathy and Positive Symptoms Across the Psychosis Continuum 
To address aim 2 of the study (relation of symptoms to VS activity), we calculated correlations 
between VS mean percent signal change and symptom dimensions across the complete psychosis 
continuum (FEP patients and SPT participants). Importantly, right VS activity during reward 
anticipation was positively correlated with apathy (rs=.31, p=.02, adjusted p=.04), positive 
symptoms (rs=.37, p=.007, adjusted p=.014) and total symptom severity (rs=.39, p=.004, adjusted 
p=.008) (figure 4). Left VS activity was positively correlated with positive symptoms (rs=.29, 
p=.03, adjusted p=.06) but not with apathy (rs =.19, p=.18, adjusted p=.36) and total symptom 
severity (rs=.18, p=.21, adjusted p=.42).  
 
In contrast, diminished expression (right VS: rs=.07, p=.60, adjusted p=1.2); left VS: rs=-.19, 
p=.17, adjusted p=.34), depressive symptoms (right VS: rs=.22, p=.10, adjusted p=.20; left VS: 
rs=.11, p=.48, adjusted p=.96), and cognition (right VS: rs=.10, p=.48, adjusted p=.96; left VS: 
rs=.24, p=.09, adjusted p=.18) were not significantly correlated with the neural signal in the VS. 
In summary, VS activity, in particular right VS activity, was correlated with total symptom 
severity, apathy and positive symptoms.  
 
Due to the symptom overlap of apathy, positive symptoms and depressive symptoms in our 
sample we computed partial correlations to identify interaction effects between these variables. 
Importantly, the partial correlation between VS activity and positive symptoms remained 
significant in the right VS (rs=.29, p=.04), when controlling for apathy and depressive symptoms. 
In contrast the partial correlation between activation in the right VS and apathy was not 
significant (rs=.20, p=.17) when controlling for positive symptoms and depressive symptoms. 
Furthermore, ventral striatal activity was not associated with antipsychotic dose in medicated 
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patients (table S3). Finally, the inclusion of cognition and age in the partial correlations did not 
change the results and all correlations mentioned above remained significant (supplementary 
table S4).  
 
Correlation Analysis within each Subgroup of the Psychosis Continuum 
In a third step we aimed to investigate if the observed relation between right VS activity and 
symptom expression differs between subgroups of the psychosis continuum. Therefore, we 
performed correlation analysis in SPT, FEP-BPD and FEP-SZ separately (see supplementary 
table S5). FEP-SZ showed a significant correlation between PANSS Total score and right VS 
activity (rs=.60, p=.03). Furthermore, in these patients VS activity was correlated with positive 
symptoms at a trend level in the right VS (rs=.50, p=.08). FEP-BPD showed significant 
correlation between PANSS Total score and right VS activity (rs=.65 p=.02). Furthermore, 
positive symptoms were significantly associated with VS activity (right VS: rs=.65, p=.02). In 
SPT, PANSS Total score was not significantly correlated with VS activity (right VS: rs=.17, 
p=.42). However, positive symptoms were correlated with right VS activity at a trend level (right 
VS: rs=.33, p=.10).  
 
Since positive symptoms were consistently associated with ventral striatal activation, we repeated 
the ANCOVA comparing the groups within the psychosis continuum and added positive 
symptoms as an additional covariate. The main effect of group remained significant (F(2, 
45)=3.29, p=.046) indicating that the observed group differences cannot be reduced to differences 
in positive symptom levels.  
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Discussion 
To our knowledge, this is the first functional neuroimaging study to investigate the neural 
correlates of symptom expression in healthy individuals with high schizotypal traits and patients 
with broadly defined non-affective first-episode psychosis of short duration. We observed intact 
reward-related speeding and no group differences, which suggests that individuals in the 
psychosis continuum were able to perform the task in a comparable way to healthy controls. We 
found that ventral striatal activation during reward anticipation did not differ between healthy 
controls and individuals within the psychosis continuum. In contrast, individuals with first-
episode schizophrenia showed higher VS activity compared to patients with brief psychotic 
disorders and individuals with high schizotypal personality traits.  
 
Across these groups in the psychosis continuum, total symptom severity was associated with an 
increase in VS activity during reward anticipation. In particular, levels of positive symptoms 
were positively correlated with VS activation. In contrast, there was no association with 
depressive symptoms and the association with apathy was driven by positive symptoms. 
Importantly, the association between positive symptoms and VS activity remained when 
investigating each group separately.  
 
Overall, these findings suggest that increased VS activity during reward anticipation is a shared 
neural correlate of positive symptoms across the psychosis continuum. However, the observed 
group differences point towards an increase in VS activity that is specific to first-episode 
schizophrenia and cannot be reduced to symptom differences between groups.  
 
Matthias Kirschner et al. Neural Correlates of Symptom Expression in Psychosis 
 
 15 
The association of both positive symptoms and apathy with neural alterations in the ventral 
striatum has to be interpreted in light of the observed interaction of these symptom domains at the 
psychopathological level. The observed correlations suggest that in our sample apathy was at 
least partially secondary to positive symptoms and depression. In contrast, negative symptoms 
were not correlated with antipsychotics (supplementary table S3). Secondary negative symptoms 
are thought to result from other factors such as positive symptoms, depression and antipsychotics, 
while primary negative symptoms are linked to the disease process itself.49–51 Corresponding to 
our findings, a specific association of apathy but not diminished expression with positive 
symptoms and depression has been proposed previously.52 
 
At the neural level, the observed positive correlation of apathy and increased VS activity 
contrasts with previous studies, including our own, reporting a negative association in patients 
with schizophrenia.25,26,35 However, the studies showing an association of striatal hypo-activation 
and apathy were typically based on samples with more primary negative symptoms in patients 
with chronic schizophrenia.25,26 In contrast, the current study investigated a psychosis continuum 
from non-clinical participants to patients with early psychosis with a different psychopathological 
construct of apathy (partly secondary to positive and depressive symptoms). Furthermore, our 
results are consistent with findings of Morris and colleagues53 who found the same relationship of 
exaggerated VS activity with negative symptoms and total symptom severity suggesting a more 
complex picture between aberrant ventral striatal activity and psychopathology.  
 
Several aspects may explain the findings regarding VS hyperactivity in the present study. First, 
striatal responsivity to rewarding cues may be stage-dependent and vary between initial and 
chronic forms of psychosis resulting in relative hyper-activation in early psychosis and hypo-
activation in chronic schizophrenia. Second, according to Heinz and Schlagenhauf acute 
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psychotic symptom levels may influence reward dependent dopamine firing.54 In acute 
schizophrenic psychosis chaotic aberrant firing can lead to a ceiling effect for dopamine 
signaling, in which signal increase related to reward cues is no longer detectable. However, in 
patients with low to moderate positive psychotic symptoms this ceiling effect may not be reached 
and signal increase related to reward cues is still detectable. Third, our data suggest that different 
psychopathological properties of the study samples may influence striatal function during reward 
anticipation. In this context, the present findings highlight the importance of differentiating 
psychopathological constructs when investigating the neurobiological underpinnings of 
symptoms and suggest different neural mechanisms for primary and secondary negative 
symptoms.  
 
One of the main findings of the present study is the dimensional association of total symptom 
severity with VS dysfunction in the psychosis continuum. Importantly, increased striatal activity 
during reward anticipation was mostly driven by positive symptoms, which is consistent with our 
previous study in unmedicated individuals at-risk for psychosis.19 These findings are in-line with 
studies showing a relation between positive symptoms and increased hemodynamic responses to 
reward-predicting cues55 or neutral stimuli in the mesolimbic reward system21,32,56,57 in 
individuals at-risk for psychosis and patients with psychotic disorders. In contrast, a recent study 
in unmedicated patients with schizophrenia has reported a negative association between VS 
activity during anticipation of wins and losses, i.e. salience, with positive symptoms.15 The 
different results could be due to the fact that our study design included only reward conditions, 
while Nielsen and colleagues employed a salience contrast.58,59 In addition, our patients were 
treated with atypical antipsychotics. However, in our subsample of medicated patients the dose of 
atypical antipsychotics was not associated with ventral striatal activation. Furthermore, our 
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observation of an association between increased striatal activity with total symptom severity is in-
line with previous findings of elevated striatal dopamine function in positron emission 
tomography studies1,2,4,5,60,61 as well as increased striatal response in fMRI studies.19,53  
 
At the group level, we found no differences between healthy controls and individuals with 
schizotypal personality traits or first-episode psychosis in VS activation, which is consistent with 
previous results in broadly defined FEP patients and individuals at-risk for psychosis.19–22 In 
contrast, there is now meta-analytic support for reduced VS activation in patients with established 
schizophrenia,24 but results on the individual study level are very inconsistent. 15,16,23,25,31,35,59,62,63 
These mixed findings support the notion that striatal alterations in psychosis do not solely consist 
of hypo-activation but vary between different stages (early vs. chronic) and different forms of 
psychosis (schizophrenia vs. non-schizophrenia). In line with this notion, patients with first-
episode schizophrenia showed higher striatal activity compared to other individuals within the 
psychosis continuum. This effect cannot be explained by differences in symptom severity 
between groups. Thus, VS activation seems to be elevated in this group in addition to its relation 
with positive symptoms. While a mechanistic interpretation of this observation is somewhat 
speculative, this effect might indicate a more profound dysregulation of striatal dopamine 
transmission in patients with schizophrenia, possibly due to extra-striatal influences.  
  
Some limitations of our study need to be considered. First, our sample showed only mild levels of 
positive symptoms and low levels of depressive symptoms, which did not differ between patients 
and individuals with SPT. This limits the possibility to draw conclusion about the interacting 
effects of the different psychopathological domains and neural correlates for high levels of 
symptom expression. Thus, it would be important to investigate samples with a broader range of 
symptom expression on all psychosis dimensions. Furthermore, the PANSS has limitations in 
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detecting subclinical psychotic symptoms. Future studies should focus on subclinical psychotic 
symptoms in at-risk groups and healthy controls to cover the full range of the psychosis spectrum 
using other rating scales such as the Comprehensive Assessment of At-Risk Mental States 
(CAARMS) or the Structured Interview for Prodromal Syndromes (SIPS).64,65 In addition, the 
relationship between salience, value and reward prediction signals is still a matter of intense 
debate.3,53,66 However, our task design focused only on reward anticipation. It would be of high 
importance to employ tasks that allow a clear quantitative distinction between salience and value 
coding in order to specify the neural basis of negative and positive symptoms. Finally, although 
all analyses were controlled for cognition, potential influences of differences in intelligence 
between groups cannot be definitely ruled out. 
 
In conclusion, the present study provides new evidence for striatal dysfunction during reward 
anticipation as a dimensional neural correlate of symptom expression in the psychosis continuum. 
Importantly, our data suggest that increased striatal activity is associated with positive symptoms 
across individuals with schizotypal personality traits and early stages of psychosis. In-line with 
the Research Domain Criteria approach67,68, these results suggest that variance in striatal 
activation is explained by dimensional symptom expression. However, patients with first-episode 
schizophrenia show an elevated striatal activation during reward anticipation that cannot be 
reduced to symptom effects, which suggests an additional categorical effect separating this group 
from others within the psychosis continuum. These results are in line with the epidemiological 
literature that increasingly emphasizes combination of dimensional and categorical models of 
psychiatric illness.69 Thus, our data shows that a trans-diagnostic approach facilitates 
disentangling dimensional and categorical neural mechanisms in the psychosis continuum.  
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Tables 
 
Table 1. Demographic, Psychopathological and Clinical Data  
  
 Healthy Controls 
(n = 25) 
SPT Participants 
(n = 26) 
FEP patients 
(n = 26) 
Test Statistic  
(U/F/x2) 
 
Age 
 
28.8 (6.7) 
 
29.5 (10.3) 
 
24.1 (6.9) 
 
x2 = 8.08* 
Gender (f ,m) 6f, 19m 9f, 17m 5f, 21m x2 = 1.67 
Education, Years 13.9 (2.4) 15.3 (2.6) 12.1 (2.5) x2 = 16.7 *** 
Duration of illness, Months   5.4 (6.2)  
Duration of antipsychotic treatment 
in days 
 41 (30)   
Diagnosis a   SZ=13; 
BPD=13 
 
     
Chlorpromazine Equivalents (mg/d)   268.8 (244.5)  
BNSS Apathy b  8.4 (8.3) 13.6 (8.0) U = 208.5* 
BNSS Diminished Expression c  3.1 (4.5) 6.0 (6.5) U = 248.0 
BNSS Total  11.9 (8.3) 20.0 (11.9) U = 200.0* 
PANSS Positive Factor d  5.4 (2.4) 5.9 (1.7) U = 257.5 
PANSS Total  40.9 (8.7) 44.5 (10.6) U = 261.5 
CDSS Total  2.0 (2.1) 1.8 (2.5) U = 298.0 
GAF  71.2 (11.1) 63.6 (10.3) U = 199.5* 
     
Cognition e 
Cognition Score 
 
0 (.48) 
 
.64 (.64) 
 
-.27 (.62) 
 
F = 16.28*** 
MWT IQ 28.2 (3.8) 27.7 (3.4) 23.2 (5.8) F = 1.2*** 
     
Response time fmri task, in ms     
RT no reward 505.2 (68.2) 491.8 (81.5) 513.9 (91.0) F = .49 
RT low reward 471.2 (71.1) 447.5 (60.7) 488.0 (80.1) F = 2.14 
RT high reward 449.5 (71.3) 431.8 (59.4) 463.6 (81.3) F = 1.19 
Note: Data are presented as means and standard deviations. PANSS, Positive and Negative Syndrome Scale; 
BNSS, Brief Negative Symptom Scale; CDSS, Calgary Depression Scale for Schizophrenia; GAF, Global 
Assessment of Functioning; MWT IQ, Multiple Word Test Intelligence Quotient. a Diagnosis: SZ= 
Schizophrenia, BPD = Brief Psychotic Disorder. b Apathy = Avolition, Anhedonia, Asociality; c Diminished 
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Expression = Affective Flattening or Blunting, Alogia. d PANSS positive factor = P1, P3, P5, G9. e Cognition data 
were z-transformed based on the data of the HC group for each test separately. The Composite cognition score 
was computed as the mean of the z-transformed test scores on subject level. Duration of illness included the 
duration of untreated psychosis and the time period since initiation of treatment. 
***P<.001, **P<.01,*P<.05. 
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Figure Legends 
Figure 1. Symptom dimensions in the psychosis continuum. (A) Simplified model of the 
psychosis continuum and its putative separation into subgroups. Subgroups investigated in the 
present study are outlined with a red rectangle. (B) Symptom dimensions in psychosis adapted 
from Kapur and van Os.70 
 
Figure 2. At the beginning of each trial, one of three different cues was presented for 0.75s. The 
cue indicated the maximum possible amount participants could gain in that trial, i.e. high reward 
condition 0 to 2 Swiss Francs (CHF), low reward condition 0 to 0.40 CHF, or neutral condition 0 
CHF (1 CHF = 1.08 US$). After a delay the participants had to identify an outlier from three 
presented circles and press a button as fast as possible. Immediately after the button press, 
participants were notified about the money won.  
 
Figure 3. (A) and (B) illustrate the VS ROI from which the mean contrast signal for the contrast 
anticipation of high reward versus no reward was extracted. (C) Columns in bar graphs reflect 
mean contrast signal for reward anticipation in the right VS, separately for each group. Error bars 
depict +/- 1 standard error of the mean.  
 
Figure 4. Correlation plots for PANSS positive factor (A) and PANSS total score (B) with mean 
contrast signal in the right VS across the psychosis continuum. Correlation plots for PANSS 
positive factor (C) and PANSS total score (D) with mean contrast signal in the right VS for each 
group within the psychosis continuum separately; FEP-SZ (n=13), patients with FEP-BPD 
(n=13), and SPT (n=26). Correlation between VS activation and PANSS Positive Factor in FEP-
SZ: rs=.50, p=.082, in FEP-BPD: rs=.65, p=.016, and in SPT: rs=.33, p=.101. Correlation between 
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VS activation and PANSS Total Score in FEP-SZ: rs=.60, p=.029, in FEP-BPD: rs=.65 p=.016, 
and in SPT: rs=.02, p=.923. * Indicates significant correlations. 
